Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oxford Biomedica (LSE: OXB)

Last close As at 21/11/2024

458.50

▲ 8.50 (1.89%)

Market capitalisation

GBP441m

Oxford Biomedica is a UK-based company with a leading position in cancer immunotherapy and gene-based products. It is focusing its efforts on two clinical programmes, ProSavin and TroVax, and has an ocular collaboration with Sanofi-Aventis.

Latest Insights

View More

Healthcare | Flash note

Oxford Biomedica — COVID vaccine and Kymriah news encouraging

Healthcare | edison tv

Oxford Biomedica: Edison Open House Healthcare 2022

Healthcare | Outlook

Oxford Biomedica — Driving innovation in a thriving CGT industry

Healthcare | edison tv

Oxford Biomedica – executive interview
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 4.4 46.0 (42.4)
Relative 1.7 35.1 (43.6)
52 week high/low 808.0p/297.0p

Financials

Oxford Biomedica (OXB) announced that it has signed a new three-year Master Services and Development Agreement with AstraZeneca (AZN) for future production of the AZN COVID-19 vaccine. As an expansion of the original agreement signed in September 2020, AZN will now have access to OXB’s world-class Oxbox manufacturing facilities on an as-needed basis from the start of 2023. Management expects revenues of approximately £30m from AZN in FY22 for batches of the vaccine already manufactured in 2022 under the original agreement. In addition, Novartis recently announced encouraging five-year follow-up data from the ELIANA clinical trial investigating the use of Kymriah in the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). OXB is the sole global supplier of lentiviral vector for Kymriah. We view both announcements as a positive for OXB’s future revenues. Our valuation and forecasts are currently under review.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2020A 87.7 8.3 (2.5) (2.7) N/A 23.2
2021A 142.8 33.2 19.9 22.2 20.7 13.1
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A